6 years ago

Medopad Raises $25 Million Led by Bayer to Develop AI-Based Biomarkers

  • Medopad, a UK startup developing AI-based 'digital' biomarkers using apps and wearables, has raised $25 million in Series B funding led by Bayer

  • The funding will be used to expand the scope of Medopad's developments, including building digital biomarkers and therapeutics related to heart health

  • Medopad is also working on developing diagnostics to track biomarkers related to Parkinson's, Alzheimer's and diabetes

  • The round brings the total raised by Medopad to more than $50 million, with a post-money valuation of between $200 million and $300 million.

      • ProblemHealthcare

      "Traditional methods for tracking disease progression require blood tests and doctor's visits, which are inconvenient and expensive. Medopad is developing a solution that uses apps and wearables to track digital biomarkers, which are measurable indicators of disease progression."

      Solution

      "Medopad is developing a solution that uses apps and wearables to track digital biomarkers, which are measurable indicators of disease progression. They are working with pharmaceutical and tech partners to build solutions end-to-end, leveraging advances in software and hardware to deliver solutions that were previously unattainable."

      Covered on